Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

Loss-of-Function Mutations in <i>APOC3,</i> Triglycerides, and Coronary Disease

The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071 · see citing works

Loss-of-Function Mutations in <i>APOC3</i> and Risk of Ischemic Vascular Disease

Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · see citing works

Lipoprotein lipase: from gene to obesity

Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 862 · see citing works

CLEARING FACTOR, A HEPARIN-ACTIVATED LIPOPROTEIN LIPASE

Korn, E. D. (1955) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66011-9 · Cited by 858 · see citing works

Overproduction of large VLDL particles is driven by increased liver fat content in man

Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690 · see citing works

Physiological regulation of lipoprotein lipase

Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 548 · see citing works

Lipoprotein lipase

Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 520 · see citing works

Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein

Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493 · see citing works

Targeting APOC3 in the familial chylomicronemia syndrome

Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491 · see citing works

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 1× · see citing works

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · see citing works

Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources

Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., & Egelrud, T. (1973) · Biochemistry · doi:10.1021/bi00733a026 · Cited by 332 · see citing works

Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.

Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314 · see citing works

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.

Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 283 · see citing works

Apolipoproteins: metabolic role and clinical biochemistry applications

Dominiczak, M. H., & Caslake, M. J. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011111 · Cited by 238 · see citing works

Triglyceride lpases and atherosclerosis

Olivecrona, G., & Olivecrona, T. (1995) · Current Opinion in Lipidology · doi:10.1097/00041433-199510000-00009 · Cited by 238 · see citing works

Post-Heparin Plasma Lipoprotein Lipase and Hepatic Lipase in Normal Subjects and in Patients with Hypertriglyceridaemia: Correlations to Sex, Age and Various Parameters of Triglyceride Metabolism

Huttunen, J. K., Ehnholm, C., KEKKI, M., & Nikkilä, E. A. (1976) · Clinical Science · doi:10.1042/cs0500249 · Cited by 206 · see citing works

Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201 · see citing works

Regulation of lipoprotein lipase by Angptl4

Dijk, W., & Kersten, S. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.12.005 · Cited by 199 · see citing works

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance

Adiels, M., Westerbacka, J., Soro‐Paavonen, A., Häkkinen, A. ‐., Vehkavaara, S., CASLAKE, M. J., Packard, C. J., Olofsson, S.-O., Yki‐Järvinen, H., Taskinen, M., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 197 · see citing works

Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2

Breslow, J. L., Zannis, V. I., SanGiacomo, T. R., Third, J. L., Tracy, T., & Glueck, C. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38060-3 · Cited by 174 · see citing works

Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets

Larsson, M., Vorrsjö, E., Talmud, P. J., Lõokene, A., & Olivecrona, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495366 · Cited by 169 · see citing works

The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia

Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168 · see citing works

Molecular processes that handle — and mishandle — dietary lipids

Williams, K. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35206 · Cited by 161 · see citing works

The GPIHBP1–LPL Complex Is Responsible for the Margination of Triglyceride-Rich Lipoproteins in Capillaries

Goulbourne, C. N., Gin, P., Tatar, A., Nobumori, C., Hoenger, A., Jiang, H., Grovenor, C. R. M., Adeyo, O., Esko, J. D., Goldberg, I. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.017 · Cited by 153 · see citing works

Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects

Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153 · see citing works

Hypertriglyceridemia in the genomic era: a new paradigm

Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152 · see citing works

Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins

Vilella, E., Joven, J., Fernandez‐Borja, M., Vilaró, S., Brunzell, J., Olivecrona, T., & Bengtsson-Olivecrona, G. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36948-0 · Cited by 148 · see citing works

Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins

Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145 · see citing works

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease

Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136 · see citing works

Hepatic Lipase, High Density Lipoproteins, and Hypertriglyceridemia

Chatterjee, C., & Sparks, D. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.050 · Cited by 135 · see citing works

Independent regulation of plasma apolipoprotein C–II and C–III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins

Le, N. A., Gibson, J. C., & Ginsberg, H. N. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38512-6 · Cited by 103 · see citing works

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

Hiukka, A., Fruchart‐Najib, J., Leinonen, E. S., Hilden, H., Fruchart, J., & Taskinen, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1753-z · Cited by 96 · see citing works

Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.

Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95 · see citing works

Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration

Malmendier, C. L., Lontie, J., Delcroix, C., Dubois, D. Y., Magot, T., & Roy, L. D. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90075-0 · Cited by 94 · see citing works

Angiopoietin-like Protein 4 Inhibition of Lipoprotein Lipase

Lafferty, M. J., Bradford, K. C., Erie, D. A., & Neher, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497602 · Cited by 88 · see citing works

Association of plasma lipoproteins with postheparin lipase activities.

Goldberg, I. J., Kandel, J. J., Blum, C. B., & Ginsberg, H. N. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112744 · Cited by 85 · see citing works

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70 · see citing works

Untitled work

Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64 · see citing works

Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins

Zambon, A., Schmidt, I., Beisiegel†, U., & Brunzell, J. D. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37488-5 · Cited by 62 · see citing works

Triglyceride lipases and atherosclerosis

Olivecrona, G., & Olivecrona, T. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ded83 · Cited by 62 · see citing works

Type 2 diabetes and cardiovascular disease: what next?

Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes &amp; Obesity · doi:10.1097/med.0000000000000044 · Cited by 57 · see citing works

Complexities of plasma apolipoprotein C-III metabolism

Frank M. Sacks, E. B., Zheng, C., & Jeffrey S. Cohn, E. B. (2011) · Journal of Lipid Research · doi:10.1194/jlr.e015701 · Cited by 51 · see citing works

Lipoprotein Lipase Bound to Apolipoprotein B Lipoproteins Accelerates Clearance of Postprandial Lipoproteins in Humans

Zheng, C., Murdoch, S. J., Brunzell, J. D., & Sacks, F. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000203512.01007.3d · Cited by 48 · see citing works

Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency

Inazu, A., Nakajima, K., Nakano, T., Niimi, M., Kawashiri, M., Nohara, A., Kobayashi, J., & Mabuchi, H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.02.028 · Cited by 42 · see citing works

Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects

Magkos, F., Fabbrini, E., Patterson, B. W., Eagon, J. C., & Klein, S. (2011) · Metabolism · doi:10.1016/j.metabol.2011.03.019 · Cited by 33 · see citing works

Effects of atorvastatin and n−3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity

Chan, D. C., Nguyen, M. N., Watts, G. F., Ooi, E. M. M., & Barrett, P. H. R. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28422 · Cited by 29 · see citing works

Ex VivoMeasurement of Lipoprotein Lipase-Dependent Very Low Density Lipoprotein (VLDL)-Triglyceride Hydrolysis in Human VLDL: An Alternative to the Postheparin Assay of Lipoprotein Lipase Activity?1

Pruneta‐Deloche, V., Autran, D., Ponsin, G., Marçais, C., Duvillard, L., Vergès, B. L., Berthézène, F., & Moulin, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7261 · Cited by 26 · see citing works

Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells

Huard, K., Bourgeois, P., Rhainds, D., Falstrault, L., Cohn, J. S., & Brissette, L. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.005 · Cited by 18 · see citing works

Binding of lipoprotein lipase to apolipoprotein B-containing lipoproteins

Carrero, P., Gómez‐Coronado, D., Olivecrona, G., & Lasunción, M. A. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00209-x · Cited by 17 · see citing works

Apolipoprotein B-100–Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations

Ooi, E. M. M., Russell, B. S., Olson, E., Sun, S. Z., Diffenderfer, M. R., Lichtenstein, A. H., Keilson, L., Barrett, P. H. R., Schaefer, E. J., & Sprecher, D. L. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238493 · Cited by 16 · see citing works

Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism

Diffenderfer, M. R., Brousseau, M. E., Millar, J. S., Barrett, P. H. R., Nartsupha, C., Schaefer, P. M., Wolfe, M. L., Dolnikowski, G. G., Rader, D. J., & Schaefer, E. J. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m019570 · Cited by 16 · see citing works

Heparin-decasaccharides impair the catabolism of chylomicrons

Chevreuil, O., Hultin, M., ØSTERGAARD, P., & Olivecrona, T. (1996) · Biochemical Journal · doi:10.1042/bj3200437 · Cited by 15 · see citing works

Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men

Chan, D. C., Watts, G. F., Ooi, E. M. M., Chan, D. T., Wong, A. T. Y., & Barrett, P. H. R. (2011) · Metabolism · doi:10.1016/j.metabol.2011.03.003 · Cited by 13 · see citing works

Plasma adiponectin concentration is strongly associated with VLDL-TG catabolism in postmenopausal women

Lapointe, A., Tchernof, A., Lamarche, B., Piché, M., Weisnagel, J., Bergeron, J., & Lemieux, S. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.10.007 · Cited by 10 · see citing works

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601 · see citing works

Dysregulated lipid metabolism links NAFLD to cardiovascular disease

Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 558 · see citing works

The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity

Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524 · see citing works

Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease

ter Horst, K. W., & Serlie, M. J. M. (2017) · Nutrients · doi:10.3390/nu9090981 · Cited by 365 · see citing works

Dietary Fructose and the Metabolic Syndrome

Taskinen, M., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 298 · see citing works

Causes and consequences of hypertriglyceridemia

Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239 · see citing works

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196 · see citing works

Role of lipoprotein lipase in lipid metabolism

Olivecrona, G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000297 · Cited by 189 · see citing works

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164 · see citing works

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study

Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · see citing works

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity

Taskinen, M., Söderlund, S., Bogl, L. H., Hakkarainen, A., Matikainen, N., Pietiläinen, K. H., Räsänen, S., Lundbom, N. M. I., Björnson, E., Eliasson, B., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12632 · Cited by 118 · see citing works

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

Taskinen, M., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 104 · see citing works

Triglycerides to high-density lipoprotein–cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes

Quispe, R., Martin, S. S., & Jones, S. R. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000241 · Cited by 99 · see citing works

Kinetics of plasma triglycerides in abdominal obesity

Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 94 · see citing works

Triglyceride-rich lipoproteins and remnants: targets for therapy?

Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90 · see citing works

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Taskinen, M., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90 · see citing works

Triglycerides and cardiovascular disease

Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 83 · see citing works

Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward

Williams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 81 · see citing works

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans

Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144079 · Cited by 81 · see citing works

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk

van Capelleveen, J. C., Moens, S. J. B., Yang, X., Kastelein, J. J. P., Wareham, N. J., Zwinderman, A. H., Stroes, E. S. G., Witztum, J. L., Hovingh, G. K., Khaw, K., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309007 · Cited by 71 · see citing works

Hypertriglyceridemia—causes, significance, and approaches to therapy

Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66 · see citing works

SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids

Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 66 · see citing works

Obstructive sleep apnea and effects of continuous positive airway pressure on triglyceride-rich lipoprotein metabolism

Drager, L. F., Tavoni, T. M., Silva, V. M., Santos, R. D., Pedrosa, R. P., Bortolotto, L. A., Vinagre, C. G. C., Polotsky, V. Y., Lorenzi‐Filho, G., & Maranhão, R. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m083436 · Cited by 63 · see citing works

Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance

Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 65 · see citing works

Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia

Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55 · see citing works

LDL Cholesterol Rises With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data

Laclaustra, M., López‐García, E., Civeira, F., García‐Esquinas, E., Graciani, A., Guallar‐Castillón, P., Banegas, J. R., & Rodríguez‐Artalejo, F. (2018) · Diabetes Care · doi:10.2337/dc18-0372 · Cited by 55 · see citing works

ApoCIII: A multifaceted protein in cardiometabolic disease

D’Erasmo, L., Costanzo, A. D., Gallo, A., Bruckert, É., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 52 · see citing works

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47 · see citing works

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables

Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 43 · see citing works

The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate-Restricted Diets

Norwitz, N. G., Soto-Mota, A., Kaplan, B., Ludwig, D. S., Budoff, M. J., Kontush, A., & Feldman, D. (2022) · Metabolites · doi:10.3390/metabo12050460 · Cited by 41 · see citing works

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 39 · see citing works

Biosynthesis and Metabolism of ApoB-Containing Lipoproteins

Borén, J., Taskinen, M., & Packard, C. J. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062222-020716 · Cited by 43 · see citing works

Clinical significance of small dense low‐density lipoprotein cholesterol measurement in type 2 diabetes

Hirano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14398 · Cited by 31 · see citing works

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations

Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30 · see citing works

Interpreting lipoproteins in nonalcoholic fatty liver disease

Nemes, K., & Åberg, F. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000427 · Cited by 29 · see citing works

Fasting and Nonfasting Triglycerides in Cardiovascular and Other Diseases

Pitha, J. V., Kovář, J., & Blahová, T. (2015) · Physiological Research · doi:10.33549/physiolres.933196 · Cited by 24 · see citing works

Unravelling lipoprotein metabolism with stable isotopes: tracing the flow

Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21 · see citing works

Metabolism of Triglyceride-Rich Lipoproteins

Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22 · see citing works

Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk

Martins, M. C., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2024) · Liver International · doi:10.1111/liv.16117 · Cited by 20 · see citing works

Effects of PNPLA3 I148M on hepatic lipid and very‐low‐density lipoprotein metabolism in humans

Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Henricsson, M., Ripatti, P., Ripatti, S., Palotie, A. V., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13375 · Cited by 16 · see citing works

Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects

Maraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 15 · see citing works

Diets with low n-6:n-3 PUFA ratio protects rats from fructose-induced dyslipidemia and associated hepatic changes: Comparison between 18:3 n-3 and long-chain n-3 PUFA

Sakamuri, A., Sakamuri, S. S. V. P., Kona, S. R., Jeyapal, S., & Ibrahim, A. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102082 · Cited by 13 · see citing works

Hypertriglyceridemia Associated With Abdominal Obesity

Carpentier, A. C. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306412 · Cited by 12 · see citing works

Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025

Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 45 · see citing works

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans

Adiels, M., Mardinoğlu, A., Taskinen, M., & Borén, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00342 · Cited by 11 · see citing works

Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes

Hirano, T. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65164 · Cited by 9 · see citing works

Lean adolescents with insulin resistance display higher angiopoietin like protein 3, ApoC-III and chylomicron remnant dyslipidemia

Gutiérrez-Castro, K. P., González, A. P., Caccavello, R. J., Garay‐Sevilla, M. E., & Gugliucci, A. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.016 · Cited by 9 · see citing works

Triglyceride lowering 2.0: back to the future?

Packard, C. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz810 · Cited by 9 · see citing works

Association between metabolic syndrome and left ventricular geometric change including diastolic dysfunction

Lee, S. J., Kim, H., Oh, B. K., Choi, H., Sung, K., Kang, J., Lee, M. Y., & Lee, J. (2022) · Clinical Cardiology · doi:10.1002/clc.23838 · Cited by 8 · see citing works

Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment

Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7 · see citing works

More pieces of the fructose puzzle

Stanhope, K. L. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12644 · Cited by 7 · see citing works

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target

Björnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 7 · see citing works

Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism

Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000348 · Cited by 5 · see citing works

Relationship of obesity, low-density lipoprotein cholesterol and myocardial perfusion in patients with risk factors and without atherosclerotic cardiovascular diseases

Борисович, С. В., Ansheles, A. A., Сергиенко, И. В., & Boytsov, S. A. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2734 · Cited by 5 · see citing works

Plasma metabolites, systolic blood pressure, lifestyle, and stroke risk: A prospective cohort study

Zhang, C., Li, M., Yang, M., Lin, J., Huang, J., Lin, Y. C., Chen, X., Liang, Y., Yang, Y., Yu, Z., et al. (2024) · International Journal of Stroke · doi:10.1177/17474930241293408 · Cited by 4 · see citing works

A higher glycemic response to oral glucose is associated with higher plasma apolipoprotein C3 independently of BMI in healthy twins

Bozzetto, L., Berntzen, B. J., Kaprio, J. A., Rissanen, A., Taskinen, M., & Pietiläinen, K. H. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.10.005 · Cited by 4 · see citing works

Genetic Evidence for Causal Effects of Circulating Remnant Lipid Profile on Cerebral Hemorrhage and Ischemic Stroke: A Mendelian Randomization Study

Dai, L., Lyu, L., Zhan, W.-Y., Jiang, S., & Zhou, P. (2025) · World Neurosurgery · doi:10.1016/j.wneu.2024.123649 · Cited by 3 · see citing works

Enzymes | Lipoprotein Lipase

Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2 · see citing works

Induction of obesity by a high-carbohydrate diet in zebrafish modulates genes related to feeding behavior and inflammation

Virote, B. D. C. R., da Silva, K. C. D., Júnior, R. E. M., Carneiro, W. F., Valadares, L. P. D. A., de Souza, S. P., Guimarães, I. G., Cagnini, D. Q., Godard, A. L. B., Vianna, A. R. D. C. B., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123807 · Cited by 1 · see citing works

Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia

Chang, Y.-H., Lin, D.-Y., Tsai, C.-L., Liang, C.-H., Yu, Y., Hsieh, Y., Chuang, J.-Y., Chen, Y., Yeh, H., & Lin, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010068 · Cited by 1 · see citing works

Anti-Obesity Effect of Jeju Roasted Citrus Peel Extract in High-Fat Diet-Induced Obese Mice and 3T3-L1 Adipocytes Via Lipid Metabolism Regulation

Bae, S., Kang, S., Ko, H., Park, J., & Jun, W. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2023.k.0299 · Cited by 1 · see citing works

Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System

Kovrov, O. (2019) · KTH Publication Database DiVA (KTH Royal Institute of Technology)

Lipoproteins in the postprandial state: Studies on the metabolism of triglyceride-rich lipoproteins using multicompartmental models

Björnson, E. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Biomarkers in Disease: Diabetes Methods, Discoveries and Applications

de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Chaves‐Filho, A. B., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_20-1

Biomarkers in Disease: Diabetes Methods, Discoveries, and Applications

de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Filho, A. D. B. C., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_20

Calculated Excess-Triglyceride Based on the Friedewald Formula is a Possible Surrogate Marker for the Production of Large Very-Low Density Lipoprotein, A Post-Hoc Analysis of the PROUD48 Study

Hirano, T., Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65870

The Effect of Nutraceuticals on Lipid Profiles: A Systematic Review and Meta-Analysis

Muja, E., Floccari, L. G., Simaku, A., Grosha, K., & Laçi, I. (2026) · Current Nutrition & Food Science · doi:10.2174/0115734013417004251209211055

Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique

Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009

Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease

Konings, L. A. M., Xu, W., de Jong, V., Alings, M., Tardif, J., LINCOFF, A. M., Schwartz, G. G., Grobbee, D. E., & Cabezas, M. C. (2026) · Diabetology · doi:10.3390/diabetology7090162

Kinetics of plasma triglycerides in abdominal obesity

Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 94 · see citing works

VLDL triglyceride kinetics in lean, overweight, and obese men and women

Mittendorfer, B., Yoshino, M., Patterson, B. W., & Klein, S. (2016) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2016-1500 · Cited by 108 · see citing works

Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration

Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 133 · see citing works

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70 · see citing works

Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study

Vergès, B. L., Adiels, M., Borén, J., Barrett, P. H. R., Watts, G. F., Chan, D. C., Duvillard, L., Söderlund, S., Matikainen, N., Kahri, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2365 · Cited by 30 · see citing works